Eli Lilly Stocks Rise After Retatrutide's Head-to-Head Trial Results
Eli Lilly LLY has another weapon in the diabetes and obesity drug race. Shares rose 1.21% to $1,297.37 at 11:24 a.m. ET on October 28 as Reuters reported that its experimental…
TR
By Tom Reyes · Markets Editor
Oct 28 13:46 ETSource: TradingView
From the source
Read at tradingview.comEli Lilly Stocks Rise After Retatrutide's Head-to-Head Trial Results
Eli Lilly LLY has another weapon in the diabetes and obesity drug race. Shares rose 1.21% to $1,297.37 at 11:24 a.m. ET on October 28 as Reuters reported that its experimental retatrutide beat Ozempic on weight loss and blood sugar control. The comparison used Ozempic's highest approved diabetes dose, giving Lilly a potentially powerful selling point if retatrutide clears the remaining development
